About Clinical Trials: What They Can Mean For You?

Size: px
Start display at page:

Download "About Clinical Trials: What They Can Mean For You?"

Transcription

1 About Clinical Trials: What They Can Mean For You? Karl Cremer, PharmD and AnnKatrin Petersen, MD, MS January 25, 2012 ClinicalStudy.org Owned and operated by PRI, Inc Balfour Court, Suite 201 Carlsbad, CA P:

2 Table of Contents About Clinical Trials: What They Can Mean For You?... 3 What are Clinical Trials?... 4 Four Phases of Clinical Research... 5 Types of Clinical Trials... 6 Clinical Trials for Medical Devices... 6 Overview of a Typical Clinical Trial... 6 Comparing Typical Medical Care to Clinical Trials... 7

3 About Clinical Trials: What They Can Mean For You? Chances are that you have clicked on this link because you may be interested in participating or learning more about clinical trials also known as clinical research. We hope that the information assembled will provide you with a good understanding about clinical trials and what it might mean for you. Clinical Research doesn t really start with a clinical trial; its foundation has been laid long before. Basic Research: Like all research, it starts somewhere in someone s mind, usually a scientist. People who think and observe without pre-formed judgments are at the center of all renewal. The observations are linked by thought and sometimes, after long and arduous work, lead to new ideas and inventions like the discovery of atorvastatin (a molecule that blocks the synthesis of cholesterol in the liver, thus lowering blood cholesterol). As high blood cholesterol is a common problem for many people because it increases the risk of cardiovascular disease, the discovery of this molecule by a chemist working for Parke-Davis, Ann Arbor, Michigan in 1985 meant a great advance for millions of people. Atorvastatin, marketed by Pfizer as a calcium salt under the trade name Lipitor. Just recently, on November 30, 2011, this amazing drug came off patent, which means that there is now a generic atorvastatin on the market. Once a basic observation is described, like the HMG-CoA pathway in the liver that is responsible for the synthesis of cholesterol, hundreds of experiments are run and rerun to obtain in-depth understanding of the initial observation/s. This basic research is done in institutions that you might have heard of, e.g. National Institutes of Health (NIH), National Cancer Institute, MD Anderson Cancer Center, The Salk Institute of Biological Sciences, The Scripps Research Institute, Pharmaceutical and Biotechnology companies and Universities around the globe. 3 w w w. c l i n i c a l s t u d y. o r g

4 Pre-clinical Research: Once basic research has found sufficient evidence to demonstrate the mechanisms that cause a disease, such as in the atorvastatin example, the search for a new treatment can be initiated. Presently, many treatments are targeting very specific molecules to either block or inhibit their activation, or on the contrary to enhance or increase their activity. Other treatments may help replace important substances in your body like the replacement of thyroid hormone for patients who suffer from hypothyroidism; or they may help deliver drugs to the right place where they should be active, avoiding unnecessary exposure to the entire body. The research of these new treatments continues to be done in laboratories, test tubes, and eventually in animal models. Before any new drug can be given to a human being in a clinical trial, it has to undergo extensive testing of all aspects of potential toxicity (e.g. cardiac toxicity, cellular toxicity, resistance development, hypersensitivity). These tests are mandatory by the Food and Drug Administration (FDA). The efficacy aspect of a new molecule will also be studied in cell cultures or animal models (e.g. the activity of antibiotics is tested in culture against bacteria). These in-vitro and in-vivo tests allow the scientists and doctors to make a reasonable, data-driven assessment on how the drug will work in the human body and what the potential benefits and risks are. Another example of an important new treatment that was developed in the past decade is Herceptin, a (monoclonal antibody) drug that blocks the activation of a transmembrane protein called Her2. To view a video on Herceptin, click here. Clinical Research: So once a clinical trial begin, years of work, even decades of time, have been invested to develop a new medication (aka investigational agent, or compound ). The new medication that you might receive to treat your disease has been studied in many different experiments to understand the behavior of the compound under different conditions and in different settings. At this point the FDA and the Ministries of Health (MoH) will decide if it is sufficiently safe and beneficial to test the new compound in humans. While there might be differences between the practices in different countries, most follow similar guidelines and regulations in assessing the worthiness of a new drug or device. These guidelines are called the ICH-GCP guidelines that stand for International Conference on Harmonisation of Technical Requirements Good Clinical Practice. View the guidelines here. One critical consideration is the assessment of your (the patient s) potential benefits compared to the potential risk factors that have to weigh in favor of the benefits. If the FDA allows, an Investigational New Drug Application (INDA) to move forward, Clinical Development of this new product can finally begin. What are Clinical Trials? A clinical trial is a research study that evaluates the performance of a medical product (medication, therapy, medical device, diagnostic test, etc.) in normal volunteers (people that are healthy) or patients (people with a medical condition or disease). In a clinical trial, health care practitioners (e.g., doctors, nurses, etc.) use a specific set of procedures that are based on science (i.e., protocol) to evaluate the medical product. For example, you may be given a new drug to treat diabetes and the doctor may then interview you, and perform diagnostic tests to determine if the drug controls your blood sugar as it is supposed to. 4 w w w. c l i n i c a l s t u d y. o r g

5 Clinical Development is structured in three research phases that occur sequentially but depending on the circumstances may also occur in parallel. There is also a fourth phase that applies to drugs that have already received market approval. Four Phases of Clinical Research Clinical Development Phases Phase I Phase II Definition Benefit Risk Usually enroll healthy normal volunteers. These studies evaluate the safety, dose and treatment pattern of a new medication. These clinical trials are conducted in patients with a particular medical condition or disease that a new medication is intended to treat. The studies are designed to evaluate safety, the effectiveness of the product, and to explore different doses. The initial Phase II studies frequently include a lot of blood work and other tests to assess pharmacological parameters, such as drug metabolism and distribution. Free medical care and compensation for participation contribute to identify the safety and tolerability profile of a drug at different dosing levels. Since clinical trials evaluate medicinal products to improve medical care, your participation in a clinical trial will benefit people with disease, including yourself. You have access to potentially better treatments for your disease than those that are available to you on the market. You also benefit from free stateof-the- art medical care. If people do not participate in clinical trials, it will be virtually impossible to improve medical care. Your participation makes a difference! Being a subject in one of the first-in-men studies always carries risk because the safety profile has only been tested in animals and in in-vitro models. As every living system is different, especially between species, initial exposure to a new medication has to happen very gradual very low dose to higher doses. Phase II studies explore the investigational drug, either for the first time in patients or in a new indication, with a new dose, new formulation, or in a new drug combination. Because it is the first time that the drug is administered in a new setting, there are more unknowns about efficacy and safety. The risk factors are normally balanced out by tighter surveillance, such as more doctor visits, more blood tests etc. 5 w w w. c l i n i c a l s t u d y. o r g

6 Phase III These clinical trials are usually very large studies involving many patients and are designed to prove the safety and effectiveness of a new medication. Traditionally, the FDA requires 2 Placebo-controlled Phase III studies to prove that the drug is safe and efficacious. At this stage of drug development, a lot of clinical information about safety and efficacy is available, thus increasing the potential benefits and decreasing the potential risks. You also benefit from free state-of-the-art medical care. This is the final decisive stage of development that will determine if the FDA/MoH will approve the drug and how it will be prescribed by health care professionals. At this stage, most risk factors should have been described and the treating physician will know how to recognize, prevent, or treat these adverse events. However, every person is different, and with every person, there remains a potential of new adverse event findings. The more patients exposed to the drug, the less likely unknown safety events will be found. Phase IV (postapproval) Smaller-sized studies mostly intended to assess additional properties of a drug; these studies are not required by the FDA. Free medical care and treatment. Further reduced safety risks because more is known about the drug. Types of Clinical Trials The type of clinical trial will vary depending on: The type of medical product (medication, therapy, medical device, diagnostic test, etc.) The stage of product development (e.g., product that is already marketed, new product, etc.) Trial sponsor (e.g., government, private company, university, etc.) Some clinical trials are in normal volunteers (people that are healthy) and some are in patients (people with a medical condition or disease) Clinical Trials for Medical Devices In contrast to the development of a new medication, the clinical trials used to develop a new medical device or diagnostic test are generally of shorter duration and include fewer patients. However, the precautions and monitoring to protect patient safety and the care that you receive, is the same. Overview of a Typical Clinical Trial First, the clinical trial is reviewed and approved by an independent Institutional Review Board (IRB) or Ethics Committee (EC). The IRB/EC is a group of people, who make sure that the clinical trial, and the health care practitioners, who conduct the clinical trial, protect patient rights and safety at all times during the study. 6 w w w. c l i n i c a l s t u d y. o r g

7 Second, a doctor or nurse explains the study to you. It is important that you understand the risks, benefits, and your rights as a subject in the trial. If you agree to participate in the clinical trial, you sign an informed consent form, which indicates that you agree to participate in the study. Important - Steps one and two are designed to protect people who participate in clinical trials. One should never participate in a clinical trial if you do not understand the risks and benefits of the medical product and your rights as a participant. Third, you participate in the clinical trial, which usually consists of the following: Sign the informed consent form before any trial procedures are performed Screening procedures to make sure that you are eligible for the study and to establish a baseline Use the medical product (e.g., take a medication, be treated by a medical device, undergo a diagnostic test, etc.). This could range from a 1-2 minute diagnostic test or you could receive a new medication for months to years depending on the type of clinical trial. The healthcare practitioners monitor and measure your response to the medical product (e.g., they measure your blood pressure to see if the antihypertensive drug lowered your blood pressure). After you stop using the medical product, a follow-up visit is performed to make sure that you are not experiencing any side effects after receiving the medical product. Comparing Typical Medical Care to Clinical Trials Typical Medical Care Clinical Trial Medical care is costly and I still have co-pays. Medical care is free and you may even be paid to participate in a clinical trial. Scheduling appointments is a nightmare and I Medical visits are scheduled when you enroll have to wait so long to see the doctor. in a clinical trial and you do not have to wait to see the doctor because he/she wants to see you. I saw the doctor, but I still do not feel well. Clinical trial participants are monitored closely, and often, so you may receive better medical care. I ve seen so many doctors and they still do not know what is wrong with me. I ve tried every medication and nothing seems to work. They ran three different blood tests and no one called me with the results. Are my headaches caused by my new While there are no guarantees, the doctors and nurses who conduct clinical trials are generally more knowledgeable and know more about the latest and best therapies. The screening tests are designed to confirm the medical condition that you have. Many clinical trials evaluate new and improved medical products, so you may be able to find a product that finally works. The health care practitioners that conduct a clinical trial must monitor you closely, they will share the results with you, you have a legal right to see the results of the study, and the increased level of observation may result in better health care. Medications cause side effects. The doctor or 7 w w w. c l i n i c a l s t u d y. o r g

8 medication? I cannot reach my doctor to ask him. nurse will tell you about them, monitor you frequently, and treat any new side effects or change your medication, if necessary. You will be monitored more closely in a clinical trial. I do not know my legal rights. The doctor or nurse will explain your legal rights before you enroll in the study. They are obligated by law to make sure that you understand your legal rights. In addition, you may contact the Institutional Review Board (your advocate) to answer any questions that you might have about the trial and your rights. At ClinicalStudy.org we help connect people to meaningful clinical research. You can register for future clinical trial participation at Copyright All rights reserved by Patient Recruiters International, Inc.. For permission to repost or reprint this article, please click the request link here 8 w w w. c l i n i c a l s t u d y. o r g

Learning about Clinical Trials

Learning about Clinical Trials Learning about Clinical Trials A Guide for Individuals and Their Loved Ones INTRODUCTION Clinical trials help researchers answer important medical questions, providing information that may help with the

More information

FACTS YOU NEED TO KNOW UNITED STATES OF AMERICA

FACTS YOU NEED TO KNOW UNITED STATES OF AMERICA CLINICAL TRIALS BROCHURE FACTS YOU NEED TO KNOW Thousands of men across the United States suffer from the difficult effects of prostate cancer and often undergo treatment that does not produce optimal

More information

About Clinical Trials

About Clinical Trials About Clinical Trials A guide for people with CF and their families INSIDE Who Can Participate in a Clinical Trial? Clinical Research Basics Who Is Involved in Clinical Research? Informed Consent Your

More information

CLINICAL TRIALS AND MARKET RESEARCH

CLINICAL TRIALS AND MARKET RESEARCH CLINICAL TRIALS AND MARKET RESEARCH AAKP's role in Clinical Trials and Market Research AAKP supports innovation in the kidney space. We are actively involved in market research - to share the patient voice

More information

Brain Tumour Australia Information FACT SHEET 22 Clinical Trials: Questions and Answers

Brain Tumour Australia Information FACT SHEET 22 Clinical Trials: Questions and Answers FACT SHEET 22 Clinical Trials: Questions and Answers What is a clinical trial? Clinical trials are research studies that answer scientific questions and try to find better ways to prevent, screen for,

More information

Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development

Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development No. 1 of 10 1. regulates all the drugs products manufactured and sold in the USA. (A) EMEA (B) IND (C) FDA (D) NDA (E) OSHA

More information

You ve Got the POWER! What You Should Know About Clinical Trials

You ve Got the POWER! What You Should Know About Clinical Trials You ve Got the POWER! What You Should Know About Clinical Trials Project I.M.P.A.C.T. (Increase Minority Participation and Awareness of Clinical Trials) We want to help you and your family use medical

More information

Patient Handbook on Stem Cell Therapies

Patient Handbook on Stem Cell Therapies Patient Handbook on Stem Cell Therapies WWW.ISSCR.ORG WWW.CLOSERLOOKATSTEMCELLS.ORG Patient Handbook on Stem Cell Therapies Introduction We have all heard about the extraordinary promise that stem cell

More information

Clinical Trials A Closer Look

Clinical Trials A Closer Look The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription and over-the counter) Food Medical devices Animal feed and drugs Cosmetics

More information

A GUIDE TO THIS REFLECTIONS B RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE

A GUIDE TO THIS REFLECTIONS B RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE A GUIDE TO THIS REFLECTIONS B327-02 RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE Do you have breast cancer that has spread to outside the breast? Has your tumor tested positive for

More information

CLINICAL TRIALS: WHAT YOU NEED TO KNOW

CLINICAL TRIALS: WHAT YOU NEED TO KNOW CLINICAL TRIALS: WHAT YOU NEED TO KNOW www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National Kidney Foundation's Kidney Disease Outcomes

More information

FREQUENTLY ASKED QUESTIONS

FREQUENTLY ASKED QUESTIONS CLINICAL TRIALS FREQUENTLY ASKED QUESTIONS PARTICIPATING IN A CLINICAL TRIAL What is a clinical trial? Clinical trials are research studies that involve people. Through clinical trials, researchers find

More information

International Transfers of Personal Data at sanofi-aventis R & D

International Transfers of Personal Data at sanofi-aventis R & D International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF

More information

Clinical trials patient-education brochure

Clinical trials patient-education brochure Released November 2005 Revised January 2008 Revised March 2012 Revised July 17, 2017 Clinical trials patient-education brochure Roslyn Mannon, MD David Rothstein, MD Maria Luisa Alegre, MD, PhD Giorgio

More information

Office for Human Subject Protection. University of Rochester

Office for Human Subject Protection. University of Rochester POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,

More information

The Importance of Participating in Clinical Trials in Alzheimer s Disease. Amanda G. Smith, M.D. Medical Director USF Health Byrd Alzheimer Institute

The Importance of Participating in Clinical Trials in Alzheimer s Disease. Amanda G. Smith, M.D. Medical Director USF Health Byrd Alzheimer Institute The Importance of Participating in Clinical Trials in Alzheimer s Disease Amanda G. Smith, M.D. Medical Director USF Health Byrd Alzheimer Institute First and foremost Clinical trials and studies are a

More information

Genentech, Inc., its research partners, collaborators, assignees, licensees or designees. Invitation to Participate

Genentech, Inc., its research partners, collaborators, assignees, licensees or designees. Invitation to Participate CONSENT AND RESEARCH AUTHORIZATION TO DONATE BLOOD AND TISSUE SAMPLES FOR FUTURE RESEARCH PURPOSES YALE UNIVERSITY SCHOOL OF MEDICINE YALE-NEW HAVEN HOSPITAL 200 FR. 4 Study Title: An Open-Label, Phase

More information

Volunteering for Clinical Trials

Volunteering for Clinical Trials Volunteering for Clinical Trials Volunteering for Clinical Trials When considering volunteering for a clinical trial, it is important to make an informed decision. Below are answers to frequently asked

More information

Introduction to clinical trials Magnus Kjaer

Introduction to clinical trials Magnus Kjaer Introduction to clinical trials 2016-01-20 Magnus Kjaer One Definition of Clinical Trial NIH 2014 A research study in which one or more human subjects are prospectively assigned to one or more interventions

More information

Functional Classification of Medicine

Functional Classification of Medicine Research on Humans Functional Classification of Medicine Medicine and medical intervention can take any of five forms: (1) Therapeutic (curative): seeks to cure a disease or ailment. (2) Palliative: seeks

More information

Clinical trial information leaflet and consent

Clinical trial information leaflet and consent Informed consent 1(7) Clinical trial information leaflet and consent General You must provide sufficient information on the rights of clinical trial subjects, the purpose and nature of the trial, the methodologies

More information

Engage with us on Twitter: #Molecule2Miracle

Engage with us on Twitter: #Molecule2Miracle Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech

More information

USE OF INVESTIGATIONAL DRUGS OR BIOLOGICS IN HUMAN SUBJECTS RESEARCH

USE OF INVESTIGATIONAL DRUGS OR BIOLOGICS IN HUMAN SUBJECTS RESEARCH Policy P.11 Written By: B. Laurel Elder Created: June 3, 2013 Edited Replaces 10-9-2009 Version P.11.4 USE OF INVESTIGATIONAL DRUGS OR BIOLOGICS IN HUMAN SUBJECTS RESEARCH A. Procedure Contents this procedure

More information

"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia

From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia "From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia Damir Hamamdžić D.V.M., Ph.D. Office of Research Regulatory Affairs Rutgers University RWJMS

More information

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager From Discovery to Development of new Drugs. and pitfalls along the way by Kim Dekermendjian, PhD in Medicine BD & Key Account manager The roots of Drug Discovery Before 20 th century the term didn't exists,

More information

NON-INTERVENTIONAL STUDY ABSTRACT FOR EXTERNAL DISCLOSURE

NON-INTERVENTIONAL STUDY ABSTRACT FOR EXTERNAL DISCLOSURE NON-INTERVENTIONAL STUDY ABSTRACT FOR EXTERNAL DISCLOSURE Title: KIMS (Pfizer International Metabolic Database) Date of Abstract: 25 February 2015 Keywords: Growth hormone deficiency, Genotropin, hypopituitarism.

More information

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives

More information

HEALTH CARE PROVIDER TOOLKIT

HEALTH CARE PROVIDER TOOLKIT HEALTH CARE PROVIDER TOOLKIT A LOOK AT WHAT S INSIDE WELCOME... 3 RESOURCES FOR YOU AND YOUR STAFF... 4 Why Get Involved?... 5 Key Messages... 7 Ways to Engage... 8 Website/Blog Article... 9 Social Media

More information

Current Status and Perspectives of Placebo-controlled Studies

Current Status and Perspectives of Placebo-controlled Studies Provisional Translation (as of June 1, 2016) March 9, 2016 Current Status and Perspectives of Placebo-controlled Studies Subcommittee on Placebo-controlled Studies Kazuhiko Yamamoto, Chairperson Yoshihiro

More information

Clinical Trials: What You Need to Know

Clinical Trials: What You Need to Know Clinical Trials: What You Need to Know Knowing all you can about clinical trials can help you feel better when deciding whether or not to take part in one. This guide addresses many basic questions and

More information

OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE

OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE 1. Purpose: To describe the procedures related to the development of protocol and investigational

More information

OVERVIEW OF DIRECTIVE 2001/20. Paul Derbyshire. Background & History. Aims of Directive 2001/20

OVERVIEW OF DIRECTIVE 2001/20. Paul Derbyshire. Background & History. Aims of Directive 2001/20 OVERVIEW OF DIRECTIVE 2001/20 Paul Derbyshire Background & History CONDUCT OF TRIALS III/3976/88 (July 1991) ICH/135/95 (January 1997) 2001/20 75/318 Q,S,E Testing Part 4B: GCP 91/507 MEDICINAL PRODUCTS

More information

MAINTENANCE OF THE ICH GUIDELINE ON NON-CLINICAL SAFETY STUDIES FOR THE CONDUCT OF HUMAN CLINICAL TRIALS FOR PHARMACEUTICALS M3(R1)

MAINTENANCE OF THE ICH GUIDELINE ON NON-CLINICAL SAFETY STUDIES FOR THE CONDUCT OF HUMAN CLINICAL TRIALS FOR PHARMACEUTICALS M3(R1) INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE MAINTENANCE OF THE ICH GUIDELINE ON NON-CLINICAL

More information

Introduction to clinical trials

Introduction to clinical trials Introduction to clinical trials Definition of a clinical trial A research activity that involves administration of a test treatment to some experimental unit in order to evaluate the treatment. Key words

More information

From Bench to Bedside. Russ H. Read June 23, 2014

From Bench to Bedside. Russ H. Read June 23, 2014 From Bench to Bedside Russ H. Read June 23, 2014 Talent Required Scientists, clinicians, technicians, chemists, biologists, pharmacologists, toxicologists, research associates, regulatory experts, manufacturing

More information

How To Design A Clinical Trial. Statistical Analysis. Gynecologic Cancer InterGroup

How To Design A Clinical Trial. Statistical Analysis. Gynecologic Cancer InterGroup How To Design A Clinical Trial Statistical Analysis Andrew Embleton PhD student/medical Statistician MRC Clinical Trials Unit at UCL At what points do you need to consider statistics? At what points do

More information

FDA Drug Approval Process Vicki Seyfert-Margolis, Ph.D.

FDA Drug Approval Process Vicki Seyfert-Margolis, Ph.D. Speaker Comparing The Effectiveness Of New Drugs: Should The FDA Be Asking 'Does It Work' Or 'Does It Work Better'? Vicki L. Seyfert-Margolis, PhD Senior Advisor, Science Innovation and Policy U.S. Food

More information

A LOOK AT WHAT S INSIDE

A LOOK AT WHAT S INSIDE ADVOCACY TOOLKIT A LOOK AT WHAT S INSIDE WELCOME... 3 RESOURCES FOR YOU... 4 Why Get Involved?... 5 Key Messages... 6 Ways to Engage... 7 RESOURCES FOR YOUR MEMBERS... 8 Fact Sheet: Did You Know?... 9

More information

GUIDELINES FOR CONDUCTING CLINICAL TRIALS.

GUIDELINES FOR CONDUCTING CLINICAL TRIALS. GUIDELINES FOR CONDUCTING CLINICAL TRIALS. FOREWORD The purpose of Drug Registration is to ensure that a pharmaceutical product has been adequately tested and evaluated for safety, efficacy and quality,

More information

Introduction to Drug Design and Discovery

Introduction to Drug Design and Discovery Introduction to Drug Design and Discovery Course: Drug Design Course code: 0510412 Dr. Balakumar Chandrasekaran Dr. Bilal Al-Jaidi Assistant Professors, Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy,

More information

Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015

Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015 Pediatric-Specific Provisions Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015 Requires the NIH to complete a strategic plan, and in the

More information

Clinical trial applications in the EU and US

Clinical trial applications in the EU and US Clinical trial applications in the EU and US Alain Patat, M.D. Translational Development Wyeth Research Paris, France AGAH-Club Phase 1 1 st Symposium Strasbourg 17-18 March 2005 Overview of the presentation

More information

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH PPD S CARDIOVASCULAR TEAM: OPTIMIZING TRIALS AND IMPROVING OUTCOMES APPLYING EXPERIENCE, INNOVATION AND EFFICIENCY IN THE FIGHT AGAINST CARDIOVASCULAR DISEASE

More information

Process and guidelines for applications for approval of trials involving gene and other biotechnology therapies. November 2015

Process and guidelines for applications for approval of trials involving gene and other biotechnology therapies. November 2015 Process and guidelines for applications for approval of trials involving gene and other biotechnology therapies November 2015 HRC Gene Technology Advisory Committee For further information contact: Professor

More information

S9 Nonclinical Evaluation for Anticancer Pharmaceuticals

S9 Nonclinical Evaluation for Anticancer Pharmaceuticals S9 Nonclinical Evaluation for Anticancer Pharmaceuticals This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create

More information

The Big Picture of FTD Research: Funding, Collaboration and the Scoop on Participation

The Big Picture of FTD Research: Funding, Collaboration and the Scoop on Participation The Big Picture of FTD Research: Funding, Collaboration and the Scoop on Participation 1 st Annual FTD Caregiver Conference Raleigh, NC July 12, 2011 Our objectives today Snapshot of medical research process

More information

Institute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1

Institute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1 Institute of Pharmaceutical Technology and Biopharmacy University of Pécs 2017. szeptember 22. 1 Pre-discovery Goal: Understand the disease and choose a target molecule. How: Scientists in pharmaceutical

More information

Food and Drug Administration (FDA) 101

Food and Drug Administration (FDA) 101 Food and Drug Administration (FDA) 101 What is the Food and Drug Administration (FDA)? The FDA is an agency within the U.S. Department of Health and Human Services that is responsible for protecting the

More information

Pharmaceutical companies are turning to private practices to conduct clinical trials. An insider tells you what you need to know and what to avoid in

Pharmaceutical companies are turning to private practices to conduct clinical trials. An insider tells you what you need to know and what to avoid in Pharmaceutical companies are turning to private practices to conduct clinical trials. An insider tells you what you need to know and what to avoid in order to reap the benefits. 26 Practical Dermatology

More information

European Academy of Hospital Pharmacy Biotechnology Educational Summit. Clinical trials David Gerrett (Acknowledgment Mark Howells)

European Academy of Hospital Pharmacy Biotechnology Educational Summit. Clinical trials David Gerrett (Acknowledgment Mark Howells) European Academy of Hospital Pharmacy Biotechnology Educational Summit Clinical trials David Gerrett (Acknowledgment Mark Howells) Objectives Have an appreciation and overview of clinical trials Understand

More information

Unpacking Expanded Access to Investigational Drugs and Biologics

Unpacking Expanded Access to Investigational Drugs and Biologics Unpacking Expanded Access to Investigational Drugs and Biologics When All Else Fails Richard Klein Office of Health and Constituent Affairs Food and Drug Administration September 13, 2016 FDA Drug Approval

More information

Orphan Medicinal Products

Orphan Medicinal Products Development process of Orphan Medicinal Products 1 Did you know that... A rare disease is officially defined as a lifethreatening or chronically debilitating condition that affects no more than 5 in 10,000

More information

EIGHT BASIC ELEMENTS OF INFORMED CONSENT

EIGHT BASIC ELEMENTS OF INFORMED CONSENT 1/6 This guidance addresses: o Eight Basic elements of informed consent o Additional elements of informed consent o Other information required by the IRB EIGHT BASIC ELEMENTS OF INFORMED CONSENT Required

More information

Defining Clinical Benefit in Clinical Trials: FDA Perspective

Defining Clinical Benefit in Clinical Trials: FDA Perspective Defining Clinical Benefit in Clinical Trials: FDA Perspective Jessica J. Lee, MD, MMSc Medical Team Leader Division of Gastroenterology and Inborn Errors Products Center for Drug Evaluation and Research

More information

Niemann Pick Disease Clinical Trials

Niemann Pick Disease Clinical Trials 1 Niemann Pick Disease Clinical Trials This is an exciting and enviable time for the NPD community with several clinical trials currently in the news. It can be a confusing time too as families try to

More information

WHITE PAPER. Creating a Risk Mitigation Plan for Your Phase 1 Studies

WHITE PAPER. Creating a Risk Mitigation Plan for Your Phase 1 Studies WHITE PAPER Creating a Risk Mitigation Plan for Your Phase 1 Studies Introduction When it comes to Phase 1 studies, it is typical for research sites to have SOPs which cover how to handle emergencies that

More information

Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS

Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL INVESTIGATIONAL MEDICINAL PRODUCTS' (NIMPS) (REV. 1, MARCH 2011)

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL INVESTIGATIONAL MEDICINAL PRODUCTS' (NIMPS) (REV. 1, MARCH 2011) Ref. Ares(2011)300458-18/03/2011 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public health and Risk assessment Pharmaceuticals Brussels, 18/03/2011 SANCO/C/8/SF/cg/a.5.001(2011)332855

More information

Docket #: FDA-2018-D-3268

Docket #: FDA-2018-D-3268 Subject: Comment on FDA Draft Guidance for Industry Titled Rare Diseases: Early Drug Development and the Role of Pre-Investigational New Drug Application Meetings Docket #: FDA-2018-D-3268 ARM is an international

More information

BIOSTATISTICAL METHODS

BIOSTATISTICAL METHODS BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH Phase 0 Trials: EARLY-PHASE CLINICAL TRIALS Steps to New Drug Discovery Get idea for drug target Develop a bioassay Screen chemical compounds

More information

Understanding clinical research trials

Understanding clinical research trials Understanding clinical research trials Dr. Isabelle Fleury Medical Hemato-oncologist Hôpital Maisonneuve-Rosemont CIUSSS de l Est-de-l Île-de-Montréal Goals of this presentation Better understand clinical

More information

Equipment and preparation required for one group (2-4 students) to complete the workshop

Equipment and preparation required for one group (2-4 students) to complete the workshop Your career today is a Pharmaceutical Statistician Leaders notes Do not give to the students Red text in italics denotes comments for leaders and example answers Equipment and preparation required for

More information

STATEMENT SANDRA KWEDER, M.D DEPUTY DIRECTOR, OFFICE OF NEW DRUGS CENTER FOR DRUG EVALUATION AND RESEARCH U.S. FOOD AND DRUG ADMINISTRATION BEFORE THE

STATEMENT SANDRA KWEDER, M.D DEPUTY DIRECTOR, OFFICE OF NEW DRUGS CENTER FOR DRUG EVALUATION AND RESEARCH U.S. FOOD AND DRUG ADMINISTRATION BEFORE THE DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville MD 20857 STATEMENT OF SANDRA KWEDER, M.D DEPUTY DIRECTOR, OFFICE OF NEW DRUGS CENTER FOR DRUG EVALUATION

More information

GENENTECH PROVIDES UPDATE ON PIPELINE AGENTS AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETING

GENENTECH PROVIDES UPDATE ON PIPELINE AGENTS AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETING NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Diane Schrick (650) 225-1599 Advocacy Contact: Kristin Reed (650) 467-9831 GENENTECH PROVIDES UPDATE ON PIPELINE AGENTS AT

More information

Preclinical studies needed in the development of human pharmaceutical drugs role of toxicology and risk assessment

Preclinical studies needed in the development of human pharmaceutical drugs role of toxicology and risk assessment Preclinical studies needed in the development of human pharmaceutical drugs role of toxicology and risk assessment Hubert Dirven Lead Validation Unit - NPI Amersham Health (GE Healthcare), Oslo Preclinical

More information

5 key characteristics

5 key characteristics Biosimilars 5 key characteristics Biologics are medicinal products derived from living organisms. 1 Their use has impacted the treatment of a variety of diseases. 1 Patents for many biologics will soon

More information

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products. 1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended

More information

Information and resources for African Americans living with multiple myeloma and their caregivers

Information and resources for African Americans living with multiple myeloma and their caregivers For African Americans living with Multiple Myeloma Information and resources for African Americans living with multiple myeloma and their caregivers Standing in the Gaap: An initiative created to help

More information

Technical Guidance on Development of In Vitro Companion Diagnostics and Corresponding Therapeutic Products

Technical Guidance on Development of In Vitro Companion Diagnostics and Corresponding Therapeutic Products Administrative Notice December 26, 2013 To: Division of Pharmaceutical Affairs, Prefectural Health Department (Bureau) From: Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry

More information

Acceptance of Foreign Clinical Data A U.S. Perspective

Acceptance of Foreign Clinical Data A U.S. Perspective Acceptance of Foreign Clinical Data A U.S. Perspective Robert L. Justice, M.D., M.S. 9 th Kitasato University Harvard School of Public Health Symposium Disclaimer The views expressed in this presentation

More information

FRDA CLINICAL TRIALS. Susan L. Perlman, M.D. Clinical Professor of Neurology UCLA Medical Center. Meeting

FRDA CLINICAL TRIALS. Susan L. Perlman, M.D. Clinical Professor of Neurology UCLA Medical Center. Meeting FRDA CLINICAL TRIALS Susan L. Perlman, M.D. Clinical Professor of Neurology UCLA Medical Center US STUDIES FUNDED BY FARA, MDA, NAF, AND NIH FOR FA 18 16 14 12 10 8 6 4 2 0 1997 1998 1999 2000 2001 2002

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS European Medicines Agency London, 24 January 2008 Doc. Ref. EMEA/CHMP/SWP/258498/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS

More information

Talking to Active Investigators: Interview Findings

Talking to Active Investigators: Interview Findings April 5, 2017 Talking to Active Investigators: Interview Findings Terri Hinkley RN, BScN, MBA, CCRC Association for Clinical Research Professionals (ACRP) Active Investigator Interviews Active Investigator:

More information

A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN

A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN A SHORT GUIDE TO THE PROCEDURE FOR A CLINICAL TRIAL APPLICATION IN THE KINGDOM OF BAHRAIN Version 1 - June 2017 A Short Guide For CT Application 1 2 A Short Guide For CT Application DEFINITIONS Clinical

More information

Clinical trials for brain tumours

Clinical trials for brain tumours Clinical trials for brain tumours The purpose of clinical trials for brain tumour patients is to gain a better understanding of these tumours and improve diagnosis and treatment. Some trials also seek

More information

Clinical Supply Packaging for Biological Products

Clinical Supply Packaging for Biological Products Clinical Supply Packaging for Biological Products Part 2 of the Clinical Supply Knowledge Share Series: Understanding and Delivering your Global Clinical Supply Chain Almac Clinical Services Clinical Supply

More information

Leukemia / Bone Marrow Transplant (BMT) Program of British Columbia

Leukemia / Bone Marrow Transplant (BMT) Program of British Columbia Leukemia / Bone Marrow Transplant (BMT) Program of British Columbia Patient Education Manual Research Module 1. Leukemia/BMT Daycare Outpatient Unit 2. Cell Separator Unit (CSU) 3. Outpatient Clinics 4.

More information

Introduction to Clinical Research

Introduction to Clinical Research Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that

More information

These are dramatic cases that captured public attention and led to the development of regulations designed to protect research participants.

These are dramatic cases that captured public attention and led to the development of regulations designed to protect research participants. Clinical Trials Every year hundreds of thousands of people in the United States and Canada are enrolled in clinical trials -- in studies designed to find better ways to treat illnesses. Many trials involve

More information

Attachment B: A Guideline for Writing a Clinical Protocol for CPRN

Attachment B: A Guideline for Writing a Clinical Protocol for CPRN Attachment B: A Guideline for Writing a Clinical Protocol for CPRN This document provides guidelines for protocol submission. It is only guidance, and the format in which you choose to present the information

More information

Celldex Compassionate Use Policy

Celldex Compassionate Use Policy Celldex Compassionate Use Policy Introduction Currently, none of Celldex s investigational products are available for compassionate use given their early stage of clinical development. The policy outlined

More information

MCW Office of Research Standard Operating Procedure

MCW Office of Research Standard Operating Procedure MCW Office of Research Standard Operating Procedure USE AND STORAGE OF INVESTIGATIONAL DRUGS AND BIOLOGICS Unit: Applies to: Human Research Protections Program (HRPP), Office of Research MCW/FH Faculty

More information

Comments of American Plasma Users Coalition (A-PLUS) To the Food and Drug Administration December 31, 2010

Comments of American Plasma Users Coalition (A-PLUS) To the Food and Drug Administration December 31, 2010 Comments of American Plasma Users Coalition (A-PLUS) To the Food and Drug Administration December 31, 2010 The American Plasma Users Coalition (A-PLUS) is a coalition of national patient advocacy organizations

More information

1. POLICY STATEMENT: 2. BACKGROUND:

1. POLICY STATEMENT: 2. BACKGROUND: POLICY #: RCO-201 Page: 1 of 5 1. POLICY STATEMENT: All Food and Drug Administration (FDA) regulated research conducted under an Investigational New Drug Application (IND) and managed within DF/HCC requires

More information

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities

More information

Bringing Home the Genome: the FDA s Role in Realizing Personalized Medicine Margaret Hamburg, M.D., FDA Commissioner

Bringing Home the Genome: the FDA s Role in Realizing Personalized Medicine Margaret Hamburg, M.D., FDA Commissioner 1 Bringing Home the Genome: the FDA s Role in Realizing Personalized Medicine Margaret Hamburg, M.D., FDA Commissioner February 25, 2010 I d like to thank the Personalized Medicine Coalition for inviting

More information

BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH

BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH Phase 0 Trials: EARLY-PHASE CLINICAL TRIALS CLINICAL PHASE Clinical Studies: Class of all scientific approaches to evaluate Disease Prevention,

More information

Clinical trials from CRA s point of view

Clinical trials from CRA s point of view Clinical trials from CRA s point of view Dr Jacek S Gregorczyk MPharmS, PhD Clinical Research Associate (CRA) at MDS Pharma Services UK office - a global CRO REGULATION of CLINICAL TRIALS World Medical

More information

ASIAN PATENT ATTORNEYS ASSOCIATION Recognized Group of Korea. Report to Emerging IP Rights Committee 2012, Chiang Mai

ASIAN PATENT ATTORNEYS ASSOCIATION Recognized Group of Korea. Report to Emerging IP Rights Committee 2012, Chiang Mai ASIAN PATENT ATTORNEYS ASSOCIATION Recognized Group of Korea Report to Emerging IP Rights Committee 2012, Chiang Mai SPECIAL TOPIC REPORT ON Business Methods and the Laws of Nature, As Discussed by the

More information

Orthopaedic Innovation: Bench, Bedside, Bank

Orthopaedic Innovation: Bench, Bedside, Bank Stephen P Makk, MD, MBA A Seth Greenwald, D-Phil (Oxon) Biomedical Engineering Committee American Academy of Orthopaedic Surgeons 1 1 The Patent Process www.uspto.gov 2 2 Patent: A government grant allowing

More information

Medical Devices. LATVIA LAWIN Klavins & Slaidins

Medical Devices. LATVIA LAWIN Klavins & Slaidins Medical Devices LATVIA LAWIN Klavins & Slaidins CONTACT INFORMATION Sarmis Spilbergs LAWIN Klavins & Slaidins Elizabetes 15, Riga, LV 1010, Latvia +371 67814848 sarmis.spilbergs@lawin.lv www.lawin.com

More information

The Right Prescription for Working with Investigational Drug Service at BMC

The Right Prescription for Working with Investigational Drug Service at BMC The Right Prescription for Working with Investigational Drug Service at BMC Andrew Schoch Pharmacy Intern Northeastern University Class of 2010 Hyeseon Hong, Pharm.D. IDS Pharmacy Manager What is Investigational

More information

Pharmabiotics: a Regulatory Hurdle in Europe

Pharmabiotics: a Regulatory Hurdle in Europe Pharmabiotics: a Regulatory Hurdle in Europe Dr. Magali Cordaillat-Simmons PRI Executive Scientist Raleigh, NC, USA September 8th, 2014 PHARMABIOTICS: A REGULATORY HURDLE IN EUROPE I. Introduction to Pharmabiotics

More information

Up Close and Personal

Up Close and Personal Special Report Up Close and With Personal advances in genetics, a new type of medicine has emerged: one that s tailored just for you and your DNA. Could it transform the paradigm of how we treat and prevent

More information

3. Human Biomedical Research. Defining Human Biomedical Research

3. Human Biomedical Research. Defining Human Biomedical Research PART B: SECTION III: HUMAN BIOMEDICAL RESEARCH HUMAN BIOMEDICAL RESEARCH 3. Human Biomedical Research Defining Human Biomedical Research 3.1. In this section, we consider what kinds of human biomedical

More information

Development of a new medicinal product. as. MUDr. Martin Votava, PhD.

Development of a new medicinal product. as. MUDr. Martin Votava, PhD. Development of a new medicinal product as. MUDr. Martin Votava, PhD. Development and registration of a medicinal product Costs of development: 800 mil USD Time to develop: 10 years Successfulness: 0,005%

More information

Belgium, a European leader in clinical trials

Belgium, a European leader in clinical trials Belgium, a European leader in clinical trials An attractive country for clinical trials to test innovative medicines In Europe it is nearly impossible to find other countries with as many clinical trials

More information

fact sheet 3 Introduction to Biosimilars & Regulatory Requirements

fact sheet 3 Introduction to Biosimilars & Regulatory Requirements 3 fact sheet 3 Introduction to Biosimilars & Regulatory Requirements International Alliance of Patients Organizations CAN Mezzanine 49-51 East Road London N1 6AH United Kingdom International Federation

More information

May Patient Reported Outcomes: Strategies for gaining or expanding market access ES SAMPLE PAGES SA. A FirstWord ExpertViews Dossier Report

May Patient Reported Outcomes: Strategies for gaining or expanding market access ES SAMPLE PAGES SA. A FirstWord ExpertViews Dossier Report A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in any form or by any means

More information

impact on a trial design and labeling

impact on a trial design and labeling Genotyping-impact impact on a trial design and labeling Yoshiaki Uyama,, Ph.D. Office of New Drug III (PMDA) Benefit of Pharmacogenomics Improving benefit/risk ratio More safe, more effective Adjusting

More information